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Introduction
Among all diseases, a majority of human effort has 
been allocated to fight with cancer (Amirimoghadam, 
2012). Cancer is one of the major causes of morbidity, 
mortality and disability worldwide (Haghshenas et al., 
2013). Lung cancer is a very common disease with an 
increasing trend (Bollschweiler et al., 2002). In Iran, 
after cardiovascular diseases and accidents, cancer is the 
third leading cause of death (Mousavi et al., 2009). Lung 
cancer is an important and fatal cancer a five-year survival 
rate of only 13% after the time of diagnosis (OZLU and 
BULBUL, 2005; Haraguchi et al., 2012). Cancers in Iran 
as a whole imposed 662.2 Disability Adjusted Life Years 
(DALY) per hundred thousand people and after the gastric 
cancer, the lung cancer is in the second important fatal 
cancerwith 56.3 DALY (Bollschweiler et al., 2002). 
According to classification of the America Cancer 
Society, there are two types of lung cancer: (a) small 
cell carcinoma (SCC) and (b) non-small cell carcinoma 
(NSCC), there are many forms of this cancer. This type 
of lung cancer is defined according to the type of cells in 
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Abstract
 Background: Lung cancer is a fatal malignancy with high mortality and short survival time. The aim of this 
study was to estimate survival rates of Iranian patients with lung cancer and its associate predictive factors. 
Materials and Methods: The study was conducted on 355 patients admitted to hospitals of West Azerbaijan in 
the year 2007. The patients were followed up by phone calls until the end of June 2014. The survival rate was 
estimated using the Kaplan-Meier method and log-rank test for comparison. The Cox’s proportional hazard 
model was used to investigate the effect of various variables on patient survival time, including age, sex, Eastern 
Cooperative Oncology Group (ECOG) performance, smoking status, tumor type, tumor stage, treatment, 
metastasis, and blood hemoglobin concentration. Results: Of the 355 patients under study, 240 died and 115 were 
censored.  The mean and median survival time of patients was 13 and 4.8 months, respectively. According to the 
results of Kaplan-Meier method, 1, 2, and 3 years survival rates were 39%, 18%, and 0.07%, respectively. Based 
on Cox regression analysis, the risk of death was associated with ECOG group V (1.83, 95% CI: 1 Conclusions: 
The survival time of the patients with lung cancer is very short. While early diagnosis may improve the life 
expectancy effective treatment is not available. 
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the lung tissue (Macdonald et al., 2004). The three main 
subtypes of NSCC are adenocarcinoma, squamous-cell 
carcinoma and large-cell carcinoma (Horn et al., 2012).
SCC involves dense neurosecretory granules (Rosti et 
al., 2006). Most cases arise in the larger airways (primary 
and secondary bronchi) (Collins et al., 2007). SCC is the 
most common type of lung cancer and has rapid growth 
and metastasis rate, and spreads to other organs easily. 
About 67% of cases have metastatic disease at time of 
diagnosis. This type of lung cancer is strongly associated 
with smoking (Horn et al., 2012). NSCC is often treated 
with surgery, while SCC usually responds better to 
chemotherapy and radiotherapy (Chapman et al., 2009).
Lung cancer is one of the main causes of death 
among known cancers and has the highest mortality rates 
compared to the cancers of breast, prostate and other 
multiple cancers (a person that getting more than one type 
of cancer) (Zahir and Mirtalebi, 2012). Unfortunately, it 
takes a very long time until the lung cancer symptoms 
become evident. Therefore, in most cases the disease is 
diagnosed in advanced stages (Fauci, 2008; Silvestri et 
al., 2009). 
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Survival rate of patients with any type of cancer is one 
of the most important indicators in disease control and 
evaluation of treatment methods (Klein, 2005). Taghipour 
et al reported a mean survival time of 8.5 months for 
patients with lung cancer. They reported that only 25% 
of patients had survived more than one year (Zahir and 
Mirtalebi, 2012). Drech Gross et al reported a median 
survival time of 6.5 months for patients with lung cancer 
and a one-year survival rate of 30% (Grose et al., 2014). 
Santro et al obtained median survival time of 15.7 months.
They estimated median survival time of patients 14.9 and 
22.1 months for smokers and non-smokers, respectively 
(Santoro et al., 2011). Mathew et al reporteda median 
survival time of 15.2 months with 5-years survival rate of 
11% in patients with lung cancer (Schabath et al., 2014). 
Goksel et al also reporteda median survival of 16.9 months 
with 5-year survival rate of 9% (Goksel et al., 2013). 
West Azerbaijan province is in the northwest of Iran. 
Until now, no comprehensive study has conducted to 
examine the lung cancer survival rate and its associated 
risk factors. This is the first study conducted in this 
province to estimate survival rate of patients with lung 
cancer and to determine its associated predictive factors.
Materials and Methods
In this retrospective cohort study, demographic and 
biological information of all patients with lung cancer 
admitted to university hospitals of West Azerbaijan 
province was obtained from 2007 to 2014. Demographic 
variables included age at time of diagnosis, and gender. 
Biological variables includedEastern Cooperative 
Oncology Group (ECOG) performance, smoking, tumor 
type, tumor stage, metastasis, and blood hemoglobin 
concentration. The patients were followed by the June 
2014 and their information obtained from medical records 
and through phone calls and home visits. The patients who 
lost to follow up or diedfor reasons other than lung cancer 
or was alive at the end of the study were considered as 
censored. The duration of survival time was measured 
in months from the time of diagnosis until the end of the 
study period. The event of interest was death from lung 
cancer.
The data were analyzed using Stata and R software. 
Survival rates were estimated by Kaplan-Meier method and 
compared by Log-rank test to assess the effect of various 
variables on the patients’ survival time. In addition,simple 
and multiple Cox’s regression analyses were performed. 
The assumption of hazard proportionality was checked 
by the Schenofeld residual test. The assumption was not 
rejected for any variable. Significance level for statistical 
tests was 0.05.
Results 
Of the 355 patients under study, 240 died and 115 were 
censored. About 72.1% of the patients (256 cases) were 
males and 27.9% (99 cases) were females (male to female 
ratio was 2.6). The mean age at time of diagnosis was 
63.5±13.5 (ranged from 11 to 91 years). The mean age at 
time of diagnosis for men and women was 65.0±12.4 and 
59.4±15.5 years, respectively (p=0.002). The mean and 
median survival time of patients was13 and 4.8 months, 
respectively. The mean and median survival time for men 
was 12.5 and 8.1 months and that of women was13.9 10.1 
months, respectively. The Log-rank test did not show any 
significant difference between the survival time in men 
and women (p=0.350).
According to the results of Kaplan-Meier method, 1, 
2, and 3 years survival rate of patients was 39%, 18%, and 
0.07%, respectively (Figure 1). One-year survival rate was 
38% for men and 41% for women, which log-rank test did 
Table 1. Demographic and Clinical Characteristics of 
Patients with lung Cancer 
Variables Number (%)
Sex 
 Male 256 (72.1)
 Female 99 (27.9)
Age (yr) 
 <60 137 (39.5)
 60-75 145 (41.8)
 >75 65 (18.7)
Eastern Cooperative Oncology Group 
 I,II 80 (22.8)
 III 161(45.9)
 V 110 (31.3)
Smoking Status 
 Smoker 245 (69.2)
 Non-smoker 109 (30.8)
Tumor type 
 Adenocarcinoma 80 (26.6)
 SCC 132 (43.9)
 Lung Cell 5 (1.7)
 Carcinoid & Other 58 (19.3)
 Extensive 22 (7.3)
 Limited 4 (1.3)
Tumor stage 
 I 3 (1)
 II 33 (10.5)
 III 64 (20.4)
 IV 213 (68.1)
Treatment 
 Received 186 (65)
 Not-received 101 (35)
 Metastasis 
 Yes 191 (53.8)
 No 164 (46.2)
Figure 1. Kaplan-Meier Survival Rate Estimation for 
Patients with Lung Cancer
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not showany significant difference (p=0.272).
Lung cancers based on histological classification are 
divided into three types of NSCC, SCC and carcinoid 
tumor. In this study, 71.8% of cases had NSCC, 9%had 
SCC and 19.3% had carcinoid tumor. The mean and 
standard deviation of blood hemoglobin was 11.9 (±2.2) 
mg/dl for men and was 11.2±1.9 mg/dl for women. Other 
characteristics of the patients are given in Table 1.
The results of univariate Cox regression showed that 
male patients, whose blood hemoglobin level was less 
than 14 mg/dl had a higher survival rate compared to male 
subjects with a blood hemoglobin level more than 14 md/
dl (p=0.021, HR=1.44). This variable was not significant 
for females (p=0.507, HR=1.23).
To evaluate the effect of variables on survival time, 
unadjusted univariate Cox’s regression was used. The 
results showed that age at diagnosis time, smoking status, 
tumor type, treatment, and metastasis had a significant 
effect on the survival time (Table 2). In addition, multiple 
Cox regression was used to estimate the adjusted effects 
of potential risk factors on survival time. In multiple Cox 
regression the ECOG performance, smoking status and 
treatment was significantly associated with survival time 
of patients with lung cancer. Unlike univariate regression, 
the adjusted association between lung cancer and age at 
the time diagnosis, tumor stage, and metastasis was not 
statistically significant in multiple regression analysis 
(Table 2).
Discussion
The results of this study indicated that age at the time 
of diagnosis, ECOG performance, smoking status, stage 
group, treatment, and metastasis had a significant effect 
on the patients’ survival probability. 
Based on our results, the mean age at the time 
diagnosis was consistent with to results of other studies 
conducted in Iran and other countries (Arrieta et al., 2012; 
Zahir and Mirtalebi, 2012). Although sex is one of the 
effective factors on survival time, in the current study, the 
sex was not significantly related to survival time as was 
reported by Zahir Mirtalebi et al. (2012).However, some 
studies have indicated that survival time in women is more 
than in men (Battafarano et al., 2002; Puri et al., 2010).
In this study, we indicated a significant reverse 
association between age at diagnosis and survival time, 
so that the survival time decreased with age. The hazard 
ratio for patients older than 75 years was more than two 
fold higher than patients aged 60 years or younger. Similar 
studies confirm such a finding (Puri et al., 2010; Zahir and 
Mirtalebi, 2012).
According to our findings,there was a significant 
association between ECOG performance and survival 
time. The patients in group V had the lowest survival time 
and followed by patients in group III.
In the current study, the most common type of lung 
cancer was SCC and adenocarcinomaand carcinoid were 
in the second and third most common lung cancers.
There was no significant association between tumor type 
and survival rate. This finding was consistent with the 
results of similar to other studies conducted in Iran (Zahir 
and Mirtalebi, 2012; Hajmanoochehri et al., 2014) but 
inconsistent with the results of studies carried out in other 
countries. Some studies in other countries have reported 
Table 2. The results of univariate and multiple Cox regression model
 HR(95% CI)  Median Survival time
Variables Unadjusted Adjusted (95%CI)
Sex   
 Female 1 Not included in the model 10.1 (6.1, 14.1)
 Male 1.14 (0.85, 1.54)  8.1 (5.3, 10.9)
Age (yr)   
 <60 1 1 12.2 (9.5, 15)
 60-75 1.37 (1.02, 1.83) 1.11 (0.08, 1.56) 8.3 (4.3, 12)
 75> 2.12 (1.47, 3.04) 1.21 (0.76, 1.93) 3.4 (1.7, 5.2)
Eastern Cooperative Oncology Group   
 I,II 1 1 16 (12, 21.2)
 III 1.51 (1.05, 2.17) 1.37 (0.88, 2.12) 10.8 (7.7, 5.2)
 V 2.78 (1.92, 4.2) 1.83 (1.51, 2.92) 3.7 (2, 5.4)
Smoking Status   
 Non-smoker 1 1 13.2 (11.5, 14.9)
 Smoker 1.62(1.22, 2.15) 2 (1.4, 2.83) 6 (3.9, 8.2)
Tumor type   
 NSCLC 1  10.7 (8.4, 13)
 SCLC 1.04 (0.66, 1.66) Not included in the model 12.2 (5, 19.3)
Carcinoid 0.85 (0.59, 1.23)  8 (0.0, 16.6)
 Tumor stage   
 I,II,III 1 1 11 (8, 14)
 IV 1.42 (1.04, 1.93) 1.06 (0.69, 1.61) 7 (5, 9.2)
Treatment   
 Received 1 1 12.2 (10.5, 13.9)
 Not-received 2.58 (1.94, 3.42) 2.2 (1.56, 3.8) 2.1 (1.3, 3)
 Metastasis   
 No 1 1 12.2 (9.6, 14.7)
 Yes 1.57 (1.21, 2.04) 1.28 (0.87, 1.9) 5.8 (4.4, 7.3)
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adenocarcinoma as the most common type of lung cancer 
(Haraguchi et al., 2012; Jiang et al., 2012).
There was a significant association betweentumor 
stage and survival time. Approximately, 68% of patients 
were in the stage IV. Patients with tumor stage IV had a 
hazard ratio of 1.4 compared to those with tumor stages I, 
II, or III.The results of study performed by Kawaguchi et 
Al confirmed our results (Kawaguchi et al., 2010).
Subjects who received chemotherapy, radiotherapy, 
or underwent surgery had longer survival time than 
those subjects who did not receive any treatment. This 
finding was consistent with the results of similar studies 
(Berghmans et al., 2005; Zahir and Mirtalebi, 2012).
Mitsudomietal(Mitsudomi et al., 2010) and Kawaguchi 
etal (Kawaguchi et al., 2010) reported that smoking had 
a significant effect onthe survival time. It should be 
mentioned that from 96 non-smoker patients, 75 patients 
were with stage IV tumors, and only 21 patients were in 
other tumor stages.
Metastasis was another factor that had a significant 
effecton the survival time. Patients who had metastases 
had a median survival time of 5.8 months while the 
median survival time of the patients without metastases 
was 12.2 months.
In conclusion, the survival time of the patients with 
lung cancer is very short while early diagnosis of disease 
may improve the life expectancy in patients with lung 
cancer although effective treatment is not available for 
this cancer.
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